Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)

China flag China · Delayed Price · Currency is CNY
24.30
+0.05 (0.21%)
Jul 15, 2026, 3:04 PM CST
Market Cap4.89B +16.0%
Revenue (ttm)1.74B +25.0%
Net Income286.33M +602.7%
EPS1.42 +487.7%
Shares Out 201.78M
PE Ratio17.11
Forward PE21.46
Dividend0.40 (1.65%)
Ex-Dividend DateJul 6, 2026
Volume14,427,900
Open22.53
Previous Close24.25
Day's Range22.53 - 25.38
52-Week Range19.08 - 32.62
Beta0.59
Analystsn/a
Price Targetn/a
Earnings DateAug 15, 2026

About Wuhan Hvsen Biotechnology

Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildipirosin. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Bi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,133
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300871
Full Company Profile

Financial Performance

Financial Statements